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A major characteristic of HIV infection in vivo is the 
l o s ~  of CD4' T-cells. Various mechanisms contribute 
to this T-cell depletion, including virus-induced cyto- 
pathic effects. However, the immune system also plays 
a major role, e.g. by apoptosis of T-cells, which is 
enhanced in HIV-infected individuals [ 11. An important 
immune regulatory principle based on apoptosis is 
mediated by CD95-CD95 ligand (CD95L) interaction. 
Several studies have provided evidence that the CD95- 
CD95L pathway is disturbed in HIV infection, in 
that CD95 expression is enhanced on T-cells [2-41. 
C1?95L+ macrophages are believed to deplete such 
CD95-expressing T-cells [S]. Another activation marker 
on T-cells which could contribute to their apoptosis 
is CD26 [(.I, which is expressed on the majority of 
CD4' and C1)8+ T-cells in non-infected individuals 
[ 2 ] .  CL126 has been reported to be a receptor for the 
viral protein tat  [7] ,  which has been shown to induce 
apoptosis in uninfected T-cells 181. 
HIV non-progressors, who represent about 2% of 
the participants of the Swiss HIV Cohort Study 
(SHCS), do not progress to AIDS, for still unknown 
reasons. The expression of certain mutant chemokine 
receptors as well as increased chemokine levels might 
contribute to the non-progressor status [9-111. More- 
over, as apoptosis is as low in this population as in non- 
infected individuals [12], it was of interest to examine 
whether CD95 or CD26 expression on T-cells of 
non-progressors is similar to that in non-infected 
individuals, but different from that in CDC stage A and 
B/C individuals. If this is the case, the expression of 
these molecules could serve as a useful and fast marker 
to identify non-progressor and perhaps even slow- 
progressor status. 
Therefore, the expression of CU95 and/or CI126 
on CD4+ and CD8+ T-cells of individuals in different 
disease stages was evaluated and compared to that in 
non-infected controls. Altogether, 16 HIV-infected 
non-progressors, 1 1 slow progressors, 10 individuals 
within CDC stage A and 10 patients within stage B/C 
were examined. Stages A and U / C  were defined 
according to the CDC classification 1131. The non- 
progressors were defined, in accordance with the 
literature [lo], as HIV+ for more than 0 years with a 
CD4 count constantly above 500 cells/pL, asymp- 
tomatic and undergoing no antiretroviral therapy. HIV' 
individuals with a similar profile except for a CD4 
count below .SO0 cells/pL were arbitrarily defined as 
Table 1 C1195 and/or  CD2h expression on CD4+ and CD8' T-cclk 
~~~ 
Cotidition\ Non-progressor Slow progrestor CDC \tag? A CIIC stage B,'C Control 
No. p.irticipmt\ I6 11  10 1 0  l ( 1  
Vird load (log copies/iiiLiSI)) 3.8 1 2 1.2 .3.50k(l 9 3.8(1*0.6 4.58?( ) .<I  N 1) 
(:I34 C O l l l l t  (crlls/pL+SIl) 787k241 3'13+74 54.i k 1 X4 124-t I21  N I1 
c:1x C O l l l l t  (cells/pLfSIl)  1 204-t 41 8 Y13f  174 111Xk.187 022+439 N13 
Median 741 425 .i33 00 
Median 1308 807 'I85 53 1 
(:I14- T-cell\ ('%I tnr,in-tSI)) 
(:lYI5' .i8.7f Ih."' 33.72 1.i" 53.3k 1 I " 7.5 1 i - I2  ' 45i-12 
c:lj2f, G7.3f 18."' ha .7 f (1 I7 (>7.420 '.I' .17.3-t20 a 82.8 i- i 
(:I )'l.i+C.l)2hC 25..ik12"." 25.7 * t) ' 1, 23.3i-5 S3.XI-24' I 3.6 i- i 
('I Yl.iY(:lj2(, 2'1.4-t I?.'.'' 37.6-t 15'' 3729" 14.8+12' .i3+12 
C:I)S+ T-cell\ (w, mcan+SI)) 
c:1ws ' ,57524,' 52.41-26 49.(1+ 1 (> ' 5 3 i- 21 , i h . h i l 4  
('1 ml' 26.3 -t 15" 26 3f7' 2027' l3.7-t8,' 04.3-t I 1  
< : I  Y15-C111(,- 41.8i21, '  36 2 i r l 8 '  40. It 12.' 44 8+23'  11.8f5 
12.2-t 10,' lh.8i-11.' 1 0  6*4' 0 i- 1 1 ,a 44.7i-12 
"Significant dificrence 6-om control (p<0.02); "significant difference from CDC stage H/C (p<O.O2). Viral load 
HIV Ainplicor Monitor (Rorhe 1 )iagiiostic-\ System, Rasel/Switzerland). Two- or triplecolor cytoiiietry \\-a\ pedoriiicd on pcriphcral blood 
lymphocytes using FIT(:-. I'E- or PerCP-labeled monoclonal antibodlo to C l l 4 ,  <:IlX, Cll26 (Bectori lhckinson, Llasel, Switzerland) o r  
(:lj95 (Pharmigen, Hamburg. Gcriiimy) on a FACScan (Bccton Dickiiiron). Analyris was performed using the Cellquest software. For 
\tnti,tical .inalvsis, the \tudent's unpaii-cd t-tc\t \\.as used. 
SI). \tnndard dt~viatioii; NI). not donc. 
determined using the 
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slow progressors. The median time of HIV positivity 
of the 16 non-progressors and 11 slow progressors 
investigated was 10.7 years. The viral load and the CD4 
and CD8 counts of the individuals tested are given in 
Table 1. The determination of CD95 and/or CD26 on 
peripheral CD4+ and CD8+ T-cells was done by cyto- 
fluorometry [2] . 
CD95 expression on CD4+ T-cells, be they CD26+ 
or CD26-, was lowest in healthy controls and highest 
in HIV-infected stage B/C patients (Table l),  which 
is in line with previous reports [2,3]. An intermediate 
but significantly different level of CD95 expression 
on CD4+ T-cells compared to controls and stage B/C 
patients was found in non-progressors and slow pro- 
gressors and in stage A individuals, whereas CD95 
expression on CD8+ T-cells did not markedly differ 
between the four HIV-infected groups (Table 1). 
CD26 on both CD4' and CD8+ T-cells was lowest 
in CDC stage B/C patients. In non-progressors and 
slow progressors, as well as in CDC stage A individuals, 
CD26 expression on CD4+ T-cells was statistically lower 
compared to controls, but still significantly higher 
than in stage B/C individuals. In CD8+ T-cells, CD26 
expression was similar in all HIV-positive groups, but 
drastically reduced compared to controls (Table 1). 
Our results show, first, that the expression of CD95 
or CD26 on CD4' cells is similar among non-pro- 
gressors and slow progressors as well as in stage A 
individuals, but is significantly different from that in 
stage B/C patients and control individuals. Second, in 
the CD8+ population, the expression of both activation 
markers differed significantly between infected and 
non-infected individuals, but not among the HIV- 
infected groups. Third, the marked decrease of the 
CD26+ cells, which is especially prominent among 
the CD95- population, strongly suggests a CD95- 
independent pathway of depletion of these cells. Soluble 
tat might be a likely candidate for such a pathway [8,14]. 
In conclusion, based on the CD95/CD26 expression 
on CD4+ T-cells, non-progressors or slow progressors 
differ not only from patients in the advanced stages of 
disease, but also from non-infected individuals. Thus, 
neither CD95 nor CD26 is a marker for non- or slow- 
progressor status. 
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